Earnings Call Summary | InspireMD(NSPR.US) Q1 2024 Earnings Conference
Earnings Call Summary | InspireMD(NSPR.US) Q1 2024 Earnings Conference
The following is a summary of the InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript:
以下是InspireMD Inc.(NSPR)2024年第一季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
InspireMD reported a Q1 2024 total revenue of $1.5 million, marking an increase of approximately 22% from the previous year.
The company sold a total of 2,553 CGuard stents in Q1 2024, a 25.6% increase from Q1 2023.
Gross profit for Q1 2024 was $292,000, down by 21.6% due to an increase in training costs.
There was a significant increase in Q1 2024 operating expenses, which rose by 62.1% to $7.7 million, driven largely by higher share-based compensation.
A net loss of $7.32 million or $0.21 per share was reported for Q1 2024.
InspireMD报告称,2024年第一季度的总收入为150万美元,比上年增长了约22%。
该公司在 2024 年第一季度共售出 2,553 个 cGuard 支架,比 2023 年第一季度增长了 25.6%。
由于培训成本的增加,2024年第一季度的毛利为29.2万美元,下降了21.6%。
2024年第一季度的运营支出大幅增加,增长了62.1%,达到770万美元,这主要是由于股票薪酬的增加。
2024年第一季度报告的净亏损为732万美元,合每股亏损0.21美元。
Business Progress:
业务进展:
The C-Guardians trial continues, with expected results to be presented at the Leipzig Interventional Course in 2024.
The company aims to submit a premarket approval application later this year and is targeting a US commercial launch in early 2025.
InspireMD has entered a strategic agreement with the Jacobs Institute to conduct a feasibility study of CGuard Prime.
The FDA-approved study is set to enroll its first participant in Q2 2024.
Looking ahead, the company plans to study and submit its SwitchGuard system and C-Guard TCAR stent platform for clearance in 2026.
C-Guardians试验仍在继续,预计结果将在2024年的莱比锡介入课程上公布。
该公司的目标是在今年晚些时候提交上市前批准申请,并计划在2025年初在美国商业上市。
InspireMD已与雅各布斯研究所签订战略协议,对cGuard Prime进行可行性研究。
这项经美国食品药品管理局批准的研究将在2024年第二季度招收其第一位参与者。
展望未来,该公司计划在2026年研究并提交其SwitchGuard系统和C-Guard TCAR支架平台以供审批。
More details: InspireMD IR
更多详情: InspireMD IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。